Alpha Cognition Inc., a Bristol Investor Relations client, is a clinical stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, reported financial results and a corporate update for the second quarter ending June 30, 2022.This included positive topline data from the ALPHA-1062 pivotal trial, which allows for the preparation of an NDA filing for the product.

Read the full press release here: Alpha Cognition Announces Second Quarter 2022 Results and Provides Corporate Update